The immunosuppressant drugs market in India is expected to reach a projected revenue of US$ 6,690.0 million by 2027. A compound annual growth rate of 9.1% is expected of India immunosuppressant drugs market from 2021 to 2027.
In terms of revenue, India accounted for 3.8% of the global immunosuppressant drugs market in 2020.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2027.
In Asia Pacific, China immunosuppressant drugs market is projected to lead the regional market in terms of revenue in 2027.
China is the fastest growing regional market in Asia Pacific and is projected to reach USD 9,785.3 million by 2027.
According to the UN, The share of older people, those aged 60 years or above, in India's population is projected to increase to nearly 20 % and there will be more people older than 60 years than those below 15 years by 2050 and majority of the older population reside in rural areas.
According to research conducted by the India Journal of Dental Research, dental caries affected 76.4% of the surveyed population. Oral diseases have also been linked to bacterial endocarditis, atherosclerosis, chronic obstructive lung diseases and preterm low birth weight. Periodontal health has a direct link with diabetes. This proves that majority of the Indian population are in need for preventive and restorative dental treatments.
According to the Journal of Dental Research, 52.8% of the surveyed population had been to a dentist in the past 1 year, and maximum visits were by 65–74-year-olds, 43.5% of participants responded that receiving of oral healthcare was “important only when in pain” and about 66.9% participants felt “cost” was the main barrier restricting them to visit a dentist.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Immunosuppressant Drugs Market will help companies and investors design strategic landscapes.
Monoclonal Antibodies was the largest segment with a revenue share of 73.28% in 2020.
Horizon Databook has segmented the India immunosuppressant drugs market based on calcineurin inhibitors, mtor inhibitors, antiproliferative agents, monoclonal antibodies covering the revenue growth of each sub-segment from 2016 to 2027.
According to the UN, The share of older people, those aged 60 years or above, in India's population is projected to increase to nearly 20 % and there will be more people older than 60 years than those below 15 years by 2050 and majority of the older population reside in rural areas.
According to research conducted by the India Journal of Dental Research, dental caries affected 76.4% of the surveyed population. Oral diseases have also been linked to bacterial endocarditis, atherosclerosis, chronic obstructive lung diseases and preterm low birth weight. Periodontal health has a direct link with diabetes. This proves that majority of the Indian population are in need for preventive and restorative dental treatments.
According to the Journal of Dental Research, 52.8% of the surveyed population had been to a dentist in the past 1 year, and maximum visits were by 65–74-year-olds, 43.5% of participants responded that receiving of oral healthcare was “important only when in pain” and about 66.9% participants felt “cost” was the main barrier restricting them to visit a dentist.
India Immunosuppressant Drugs Market Drug Class Outlook (Revenue, USD Million , 2016-2027)
Calcineurin Inhibitors
mTOR Inhibitors
Antiproliferative Agents
Monoclonal Antibodies
Others
India Immunosuppressant Drugs Market Application Outlook (Revenue, USD Million , 2016-2027)
Autoimmune Diseases
Organ Transplants
Other Applications
India Immunosuppressant Drugs Market Route of Administration Outlook (Revenue, USD Million , 2016-2027)
Oral
Injectables
India Immunosuppressant Drugs Market Distribution Channel Outlook (Revenue, USD Million , 2016-2027)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Reasons to subscribe to Immunosuppressant Drugs Market databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Immunosuppressant Drugs Market databook
Our clientele includes a mix of Immunosuppressant Drugs Market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the India Immunosuppressant Drugs Market, including forecasts for subscribers. This country databook contains high-level insights into India Immunosuppressant Drugs Market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
India Immunosuppressant Drugs Market, 2016-2027 (US$M)